Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HK-001 in Healthy Volunteers
NCT03651349Phase 1Active, not recruiting
- Sponsor
- Everfront Biotech Inc.
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HK-001 in amyotrophic lateral sclerosis (ALS) (8 arms), sponsored by Everfront Biotech Inc. Primary endpoints: Maximum Tolerated Dose at 48 days and Dose Limiting Toxicities at 48 days. Started Feb 2021; status: active, not recruiting.
02
Drugs
HK-001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03651349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651349.